跳至主要内容
临床试验/DRKS00015856
DRKS00015856已完成不适用

Endovascular Treatment of Patients with Critical Limb Ischemia - GIKEI

GRN Klinik Weinheim0 个研究点目标入组 50 人开始时间: 2018年11月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 100 Years(—)
性别
All

入选标准

  • Patients with PAD and critical limb ischemia.

排除标准

  • 1. Fontaine Stages I or IIa without indication for endovascular treatment.
  • 2. Acute limb-threatening ischemia of iliac and femoral arteries with indication for treatment with heparin, low-molecular heparins, new anticoagulants or cumadin.
  • 3. Candidates requiring surgical revascularization or hybrid procedures after failed endovascular treatment
  • 4. Severe renal failure, creatinine clearance <30 mL/min
  • 5. Platelet count <100x109/L
  • 6. Anemia with Hb<10.0 g/dL
  • 7. History of or condition associated with increased bleeding risk including: trauma within 30 days before the index procedure, clinically significant gastrointestinal bleeding within the last 6 months, history of apoplexy within the last 3 months, fibrinolytics within 10 days before the index procedure, intracranial, intraocular, spinal, or atraumatic intra-articular bleeding, chronic hemorrhagic disorder, known intracranial neoplasm, arteriovenous malformation, or aneurysm, sustained uncontrolled hypertension: systolic blood pressure =180 mmHg or diastolic blood pressure =100 mmHg, known significant liver disease (e.g., acute clinical hepatitis, liver cirrhosis)
  • 8. Alcohol or drug abuse within 12 months before the index procedure.
  • 9. Pregnancy, breast feeding or childbearing potential without proper contraceptive measures.
  • 10. Indication for anticoagulation or dual platelet treatment due to atrial fibrillation, aortic valve replacement, vein thrombosis, acute coronary syndrome etc.
  • 11. Unable to adhere to the study protocol.
  • 12. Severe concomitant condition or disease (e.g. life expectancy <6 months, dementia or advanced liver disease).

研究者

相似试验